Hemab Therapeutics Holdings Inc stock is traded at $45.57, with a volume of 456,906. It is up +1.06% in the last 24 hours and up +48.97% over the past month. Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Previous Close:
$45.09
Open:
$45.00
24h Volume:
456,906
Relative Volume:
0.90
Market Cap:
$2.13B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-$0.8135
Net Cash Flow:
-
1W Performance:
+12.74%
1M Performance:
+48.97%
6M Performance:
+82.28%
1Y Performance:
0.00%
1-Day Range:
$43.96$45.89
1-Week Range:
$39.96$45.89
52-Week Range:
$23.00$55.42
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Name
Hemab Therapeutics Holdings IncSector
HealthcareIndustry
BiotechnologyPhone
45 2138 7627Address
101 MAIN STREET, CAMBRIDGE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS